Department of Bioengineering and Therapeutic Sciences

The first program of its kind in the United States, the MS in AICD3 will enable its graduates to gain a competitive edge for some of the most desirable jobs in the biopharmaceutical industry and in academia.

PROJECT POLICY ANL 3

I serve as Education Coordinator for the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI), a research collaboration between UCSF, Stanford University, and the U.S. Food and Drug Administration (FDA).

Su Guo, PhD, will lead a new center to increase collaboration between clinical, translational, and discovery science in teaching and research.

Students keep pace with latest innovations through experiential options and advanced degrees.

Director, MS in AICD3


As director of post­graduate education programs, I spearhead the creation and de­vel­op­ment of new edu­ca­tion­al programs, enhancing our educational initiatives and creating unparalleled op­por­tun­i­ties for graduates in the field of drug discovery and de­vel­op­ment. My passion is anchored in...

Computational biology and protein engineering expert will focus on cultivating collaboration.

QBI publishes breakthrough on COVID-19 variants; Nevan Krogan recognized as trailblazer.

Dean Kathy Giacomini shares how the School’s recent breakthroughs and accomplishments are bringing our new strategic plan to life.

Scientists have shown for the first time that kidney cells—housed in an implantable device called a bioreactor—can survive while implanted.

A delegation from South Korea visited to sign a Memorandum of Understand (MOU) initiating potential collaborations between UCSF and Korean schools of pharmacy.